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To study the antiviral effects of lamivudine on avian leukosis virus subgroup J (ALV-J) and
its inhibitory effect on the growth of fibrosarcomas caused by acute transforming avian
leukosis virus, a series of experiments were performed in chicken embryo fibroblast
cultures and 1-day-old chickens inoculated with an acutely transforming viral stock Fu-
J (SDAU1005). This stock was prepared from an acutely fibrosarcoma of field cases
in chicken farms and contained both the replication-defective virus Fu-J carrying v-fps
oncogene and its helper virus ALV-J strain SDAU1005. The results from three different
assays in cell cultures demonstrated the significant inhibitory effect of lamivudine on
the replication of both SDAU1005 and Fu-J viruses. Furthermore, the effect was
dose dependent in the concentration range of 1–4 μg/ml. In chicken experiments,
lamivudine could decrease the viral loads of SDAU1005 and Fu-J in the plasma of
inoculated chickens, delay the appearance of acute sarcomas, and decrease chicken
mortality in the early stage. This model may be used to directly evaluate the inhibitory
effects of lamivudine on such tumors and to understand the relationship between the
replication-defective virus and its helper virus while also assessing tumor processes.
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INTRODUCTION
Avian leukosis virus (ALV) is a member of the Retroviridae family and can cause neoplastic disease
in chickens by both vertical and horizontal transmission. It can be divided into 10 subgroups
from A to J according to the viral envelope glycoprotein and neutralization test (Chesters et al.,
2002). ALV-J was ﬁrst isolated from the UK and mainly caused myeloid leukosis and hemangioma
in broilers and layers in 1991 (Payne et al., 1991, 1992; Bai et al., 1995). The epidemic of ALV-J
worldwide in the following years caused enormous economic losses for the poultry industry and
attracted signiﬁcant government attention in many countries around the world. The infection and
spread of ALV-J has been controlled eﬀectively in western countries through advanced technology
and management experience (Payne and Nair, 2012). However, it remains a signiﬁcant challenge to
monitor and control ALV-J due to the late start and huge scale of chicken ﬂocks in China, although
remarkable progress has been achieved during the last decade (Gao et al., 2010). Infection of ALV-J
is ubiquitous in almost all types of chicken especially in Chinese local breeds (Sun et al., 2010; Lai
et al., 2011; Li et al., 2013; Wang et al., 2013a; Dong et al., 2015).
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At present, eﬀective therapeutics and preventive vaccines are
unavailable because ALV-J has a high mutation rate, and the
host immune responses cannot resist viral infections eﬀectively
(Hwang and Wang, 2002; Williams et al., 2004; Wang and
Cui, 2006). Eﬀective antiviral agents can prevent the virus from
replicating, and the rational use of drugs can speed up the process
of ALV-J surveillance and control. However, the study of anti-
ALV drugs has just commenced, and it is both time consuming
and costly to select eﬀective drugs using ALV-J infection models.
This is due to the long period of at least 20 weeks to induce tumors
in chickens by classical ALV-J. Lamivudine is a type of nucleoside
derivative antiviral drug with a competitive inhibitory eﬀect on
viral DNA synthesis and extension (Kewn et al., 1997). It has been
shown to function as a nucleoside reverse transcriptase inhibitor
and can restrain the replication of human immunodeﬁciency
virus (HIV) by competition binding with cellular nucleotide both
in vitro and in vivo (Soudeyns et al., 1991; Coates et al., 1992;
Geleziunas et al., 1993; Tisdale et al., 1993; Gray et al., 1995). As a
type of retrovirus, reverse transcriptase also plays a key role in the
life cycle of ALV-J, but until now, no research has been conducted
to estimate the antiviral eﬀect of lamivudine on ALV.
To explore this area, viral stocks of acutely transforming virus
Fu-J (SDAU1005), prepared from ﬁbrosarcoma cell-free ﬁltrate
consisting of both the replication-defective virus Fu-J carrying v-
fps oncogene and its helper virus ALV-J strain SDAU1005, were
used to estimate the antiviral eﬀect of lamivudine on ALV-J. Both
subcutaneous and intraperitoneal inoculation with viral stocks
of acutely transforming virus Fu-J (SDAU1005) could induce
acute ﬁbrosarcomas in chickens within 2 weeks (Chen et al.,
2012; Wang et al., 2013b). In addition, animal experiments have
shown a positive correlation between the infective viral dose and
the average appearance time the tumor, which provided an ideal
model for antiviral screening of drugs. In this article, chicken
embryo ﬁbroblasts (CEFs) infected with viral stocks of Fu-J
(SDAU1005) were used as the target cell to prove that lamivudine
could inhibit the replication of ALV-J in cultured cells. We also
established an animal infection model using viral stocks of Fu-J
(SDAU1005) to conﬁrm that lamivudine could also inhibit the
replication of ALV-J and decrease tumor growth in vivo. The
relationship between the replication-defective virus and its helper
virus and tumor processes are also discussed.
MATERIALS AND METHODS
Cells, Virus, and Reagents
The acute transforming Fu-J virus was isolated from an ALV-J
associated acute ﬁbrosarcoma of natural cases in crossbreed
broilers (Li et al., 2012). The Fu-J (SDAU1005) viral stock
used in this study was prepared from cell-free ﬁltrate of acute
ﬁbrosarcomas mentioned above, which consisted of both the
replication-defective virus Fu-J carrying v-fps oncogene and its
helper virus, ALV-J strain SDAU1005. The Fu-J (SDAU1005) viral
stock could induce ﬁbrosarcomas in chickens rapidly (within
2 weeks) but only gave rise to a mild transformation in cultured
CEF (Chen et al., 2012). CEFs were cultured in Dulbecco’s
modiﬁed Eagle medium (DMEM; GIBCO, Shanghai, China)
with 10% FBS at 37◦C in 5% CO2 atmosphere. Lamivudine
was purchased from Glaxo Smithkline (Jiangsu, China) and
dissolved in DMEM or deionized water. The ALV-J monoclonal
antibody JE9 was kindly gifted from Qin Aijian (Qin et al., 2001).
Mouse anti-fps monospeciﬁc serumwas developed and described
previously (Wang et al., 2013b).
Cell Viability Assay
The CEF viability assay was performed using a Cell Counting
Kit-8 (CCK-8; Transgen Biotech, Beijing, China) according to
the manufacturer’s instructions. Lamivudine was dissolved and
diluted to 0, 1, 2, 3, 4, 6, 8, and 10 μg/ml with PBS buﬀer.
1.0× 105 cells suspended in DMEMwere seeded in 96-well plates
and treated with lamivudine of diﬀerent concentrations. CCK-8
solution (20 μl) was added to each well to incubate for 5 h, and
absorbance at 450 nmwas determined. The absorbance at 450 nm
of untreated cells was determined to exclude background values,
and every detection was repeated three times.
Virus Infection and Lamivudine
Treatment
Chicken embryo ﬁbroblasts were plated in 35-mm dishes
preincubated in DMEM with 1, 2, and 4 μg/ml lamivudine. The
Fu-J (SDAU1005) viral stock (2.0 MOI of SDAU1005 viruses) was
inoculated into cells 12 h later in the presence of lamivudine.
After 2-h infection, media with a diﬀerent concentration of
lamivudine were changed and maintained for 6 days. Cell
supernatants were collected every day to determine the ALV p27
antigen by ELISA (IDEXX, Beijing, China). Some of the cells were
lysed with RIPA buﬀer (Beyotime, Jiangsu, China) for western
blot analysis 6 days later. Meanwhile, RNA was extracted for real-
time PCR to quantify the copy numbers of SDAU1005 and Fu-J
virus from each group.
Detection of ALV Reverse Transcriptase
Activity
A real-time PCR method modiﬁed from the “product-enhanced
reverse transcriptase (PERT) method” was used to investigate
the inhibitory eﬀect of lamivudine on ALV reverse transcriptase
(Pyra et al., 1994; Chang et al., 1997). The commercialized ALV
reverse transcriptase used in this study was purchased from
Takara (Dalian, China). First, to generate a standardized RNA
template, the ALV-J gp85 gene was cloned into pBluescript
II-SK(+) vector that carries the T7 promoter sequence to
construct the plasmid PSK-gp85. The linear form of PSK-
gp85 was digested by Sac I restriction enzyme and used to
transcribe mRNA using the T7 in vitro Transcription Kit (Roche,
Switzerland). Next, four groups of reverse transcription reaction
were performed by the standardized mRNA template prepared
using the commercialized ALV reverse transcriptase (Takara,
Dalian, China). For groups 1, 2, and 3, 0.1, 0.2, and 0.4 μl
lamivudine water solution (1 mg/ml) was added to each reaction
and group 4 served as control, and every reaction was repeated
three times. Subsequently, real-time PCR using primers gp85-
F and gp85-R listed in Table 1 was performed to quantify the
copy numbers of cDNA (1 μl) from each group. The eﬃciency of
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reverse transcription in groups 1, 2, and 3 was analyzed according
to CT values of real-time PCR to calculate the relative enzyme
activities.
Detection of ALV-p27 Antigen in
Intracellular Samples and Cell
Supernatants of CEF Infected with Fu-J
(SDAU1005) Viral Stock
The ALV-p27 antigen was determined by ELISA according
to the manufacturer’s instructions (IDEXX, Beijing, China).
Every experiment was repeated three times. For cell supernatant
samples, supernatants were collected at the appropriate time and
stored at −80◦C. For intracellular samples, cells were collected
and lysed by rapid freeze-thaw at −80◦C and a 37◦C water bath.
Western Blot Analysis to Compare
Expression of Fu-J and its Helper Virus
Chicken embryo ﬁbroblasts infected with Fu-J virus were
lysed with RIPA buﬀer, and the protein concentrations
were determined using a BCA protein assay kit (Beyotime
Biotechnology, Beijing, China). The proteins were denatured
by heating and separated on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gels and transferred to a
nitrocellulose membrane (Millipore, USA). The membranes
were blocked with 5% skimmed milk in PBS containing 0.1%
Tween 20 (PBST) for 1 h at room temperature and incubated
with mouse anti-fps serum (Wang et al., 2013b) or mAb JE9
antibody (Qin et al., 2001) at 4◦C overnight. The expression
level of β-actin (Beyotime Biotechnology, Beijing, China) was
detected as control. The blots were washed three times with
PBST and incubated with the HRP-conjugated secondary
antibody (Sigma, USA) for 1 h at room temperature. The blots
were washed as above, and positive reactions were detected by
enhanced chemiluminescence (ECL) detecting system (Beyotime
Biotechnology, Beijing, China).
Real-time PCR to Compare Expression
of Fu-J and its Helper Virus
The expression levels of the SDAU1005 gp85 gene and
Fu-J v-fps oncogene in CEFs were determined by real-
time PCR. Primers used in this study were synthesized by
Shanghai Sangon Company (Shanghai, China) and are listed in
Table 1. Ampliﬁcation results using primers gp85-F and gp85-R
represented the copy number of the replication competent ALV-J
SDAU1005, which functions as a helper virus for the Fu-J strain.
None of the Fu-J viral genome could be ampliﬁed by primers
gp85-F and gp85-R because Fu-J virus was defective with the
env gene deleted. The ampliﬁcation results using primers fps-
F and fps-R represented the copy number of Fu-J. It is notable
that the binding sites for the primer fps-F were located in the gag
region while the binding sites for the primer fps-R were located
in the 5′ terminal of fps gene, which avoids the non-speciﬁc
ampliﬁcation of the cellular fps gene. RNA was extracted from
infected CEFs using a RNA extraction kit (Omega, USA). Total
RNA (1 μg) was reverse transcribed into ﬁrst-strand cDNA using
primeScript RTMasterMix (Takara, Dalian, China) following the
manufacturer’s instructions. Diluted cDNA, primers, and SYBR
Green Mix (Takara, Dalian, China) were used for the real-time
PCR in a ﬁnal volume of 20 μl. Real-time PCR was performed
using the following parameters: 95◦C for 30 s, followed by 40
cycles of 95◦C for 5 s, and 60◦C for 34 s. The expression levels
of those genes were normalized with the expression of chicken
β-actin mRNA. The analyses of the relative gene expression data
were performed by the 2−CT method.
To determine the viral loads in chicken plasma, absolute
quantitative real-time PCR was established. Two fragments
ampliﬁed using primers gp85-F/gp85-R and fps-F/fps-R were
cloned into PMD-18T vectors to construct the standard plasmids
PMD-gp85 and PMD-fps. Those two plasmids were diluted 109
fold to generate the standard curves. Viral RNA was extracted
from chicken plasma and reverse transcribed into ﬁrst-strand
cDNA. Real-time PCR was performed using cDNA templates,
and viral loads were calculated by the equation generated
according to the standard curve.
Chicken Experiments to Test Antiviral
and Tumor Inhibitory Effects of
Lamivudine In vivo
A total of 160 1-day-old speciﬁc pathogen-free leghorn chickens
were divided into eight groups and housed in negative pressure-
ﬁltered air isolators. The group details are as follows: chickens in
groups 1, 2, 3, and 4 and groups 5, 6, 7, and 8 were inoculated with
Fu-J virus stock subcutaneously or intraperitoneally, respectively.
As described in Table 2, chickens in groups 1, 2, and 3 and
5, 6, and 7 were injected intramuscularly with 1, 2, and 4 mg
lamivudine dissolved in 400 μl DMEM every day for 7 days.
Chickens in groups 4 and 8were injected with the same volume of
TABLE 2 | Groups of the chickens to establish the animal model.
Group No. chickens Infection route Treatment
1 20 Subcutaneous (sc.) 1 mg lamivudine
2 20 Subcutaneous (sc.) 2 mg lamivudine
3 20 Subcutaneous (sc.) 3 mg lamivudine
4 20 Subcutaneous (sc.) DMEM
5 20 Intraperitoneal (ip.) 1 mg lamivudine
6 20 Intraperitoneal (ip.) 2 mg lamivudine
7 20 Intraperitoneal (ip.) 3 mg lamivudine
8 20 Intraperitoneal (ip.) DMEM
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DMEM as control. Viral loads of SDAU1005 and Fu-J in plasma
of chickens in group 5, 6, 7, and 8 were determined by real-time
PCR every week. The occurrence, sizes of tumors, and death rates
were observed and recorded every day.
Detection of Drug-resistant Mutants in
Acute Subcutaneous Sarcomas of
Administrated Chickens
The original tumor tissue ﬁltrate was used as a primary viral
stock, and isolated viral stock was prepared from subcutaneous
tumors collected from chickens infected with primary viral
stocks. Both primary viral stock and isolated viral stock were
quantiﬁed by real-time PCR. Then, CEFs were infected with
primary viral stock and isolated viral stock, respectively, with
the same dose and cultured in DMEM with 1 μg/ml lamivudine
under the same conditions. Simultaneously, infected CEFs
cultured in DMEM without lamivudine were used as controls.
Cells were maintained for 6 days, and cell supernatants were
collected every day to measure the ALV-p27 antigen by ELISA.
Viral RNA was extracted on day 7, and both helper virus
and defective virus were quantiﬁed by real-time RT-PCR. The
inhibition ratio of lamivudine was calculated according to viral
copy numbers to estimate the inhibitory eﬀect of lamivudine
on isolated viral stock. In addition, the sequence coding for
reverse transcriptase in the ALV pol gene was ampliﬁed from
both primary viral stock and isolated viral stock to investigate
whether mutations of viral drug resistance had occurred during
administration.
Statistical Analysis
The results are presented as the means + the SEMs (N = 3). All
statistical analyses were performed using SPSS statistical software
package for Windows, version 17.0 (SPSS, Inc., Chicago, IL,
USA). Statistical comparisons were made using Student’s t-test.
Ethics Statement
The animal experiments were approved by Shandong agricultural
university animal care and use committee. The license number
was SDAUA-2014-008. Care and maintenance of all chickens
were in accordance with the guidelines of the Committee on the
Ethics of Animal of Shandong Agricultural University and the
biosecurity guidelines. Chickens suﬀering from tumors grown
to a certain degree exceed a diameter of 35 mm or those in
bad healthy state due to tumors were sacriﬁced by well-trained
operators to protect animal welfare.
RESULTS
Inhibitory Effects of Lamivudine on the
Replication of Both ALV-J Associated
Acutely Transforming Virus and its
Helper Virus In vitro
Figure 1 shows that signiﬁcant inhibitory eﬀects of lamivudine
occurred with respect to replication of both Fu-J and its helper
virus SDAU1005 in infected CEF cultures. This was based on
diﬀerent criteria in three diﬀerent assays compared with the
control without lamivudine. These criteria and assay included
ALV-p27 expression levels in cell culture supernatants by ELSA
kit (Figure 1A), speciﬁc viral genomic RNA fragment levels
in cell culture supernatants by real-time RT-PCR (Figure 1B),
and speciﬁc gp85 or fps protein expression levels in cell lysates
by western blot analysis (Figure 1C). Such inhibitory eﬀects
of lamivudine were dose dependent in the concentration range
from 1 to 4 μg/ml as indicated in Figure 1. To rule out the
possibility that the antiviral activity was due to the cytotoxicity
of the chemical, a CCK-8 cell viability assay was performed,
and this indicated that there was no toxic eﬀect of lamivudine
on CEF viability with the concentration used (data was not
included), while lamivudine with a concentration exceeding
8 μg/ml resulted in mild damage to CEF.
Lamivudine Inhibits ALV Reverse
Transcriptase Activity
As a nucleotide analog, lamivudine can inhibit HIV reverse
transcriptase activity by competition binding with natural
substrates for the enzyme. To evaluate the inhibitory eﬀects
of lamivudine on ALV reverse transcriptase activity, a real-
time PCR method modiﬁed from “PERT” was performed.
Commercialized ALV reverse transcriptase was employed in
this study. Reverse transcriptase reaction systems with diﬀerent
concentrations of lamivudine were performed using 105 copy
number of transcribed mRNA. The RT eﬃciencies of those
reactions were analyzed according to the results of real-time
PCR CT values. The results illustrated a signiﬁcant decline of
enzymatic activity in the reaction system where lamivudine was
present, which indicated a strong inhibitory eﬀect of lamivudine
on ALV reverse transcriptase activity (Table 3).
Lamivudine has a Significant Inhibitory
Effect on the Growth of Subcutaneous
Tumors Induced by Fu-J (SDAU1005)
Viral Stock
To determine whether lamivudine had inhibitory eﬀect on the
growth of subcutaneous tumors induced by Fu-J, 80 1-day-
old chickens were divided into four groups randomly and
subcutaneously inoculated with the same dose of Fu-J. Chickens
in groups 1, 2, and 3 were injected intramuscularly with 1, 2,
and 4 mg lamivudine, respectively, for 7 days, while chickens
in group 4 were inoculated with the same amount of PBS and
served as a control group. The dynamic growth of subcutaneous
tumors induced by Fu-J virus was investigated every day, and
chickens were sacriﬁced when the tumors had grown to a certain
extent. The results showed that subcutaneous tumors appeared
approximately 5 days after inoculation and measured up to
4 cm in diameter at 15 days with malignant rapid growth
(Figure 2A). However, subcutaneous tumors occurred later in
chickens injected with lamivudine compared with those injected
with PBS. Subcutaneous tumors could be detected after 6, 7,
and 9 days after inoculation of chickens injected with 1, 2,
and 4 mg lamivudine, respectively (Figure 2A). Moreover, the
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FIGURE 1 | Inhibitory effects of lamivudine in different concentrations on replication of Fu-J and its helper virus in CEF cells infected with Fu-1 stock.
(A) Comparisons of ALV p27 antigen levels in cell culture supernatants by ELASA. The vertical axis represents the s/p values in ELISA, the cut-off value of positive
criteria was 0.2. (B) Comparisons of expression level of genomic RNA fragments gp85 specific to SDAU1005 and fps to Fu-J by real-time PCR. The expression
levels were normalized with the expression level of chicken β-actin mRNA and performed by using the 2−CT method. Differences in the expression level were
assessed by Student’s t-tests. (A,B) Differences were considered significant when p < 0.01 (∗), highly significant when p ≤ 0.01 (∗∗) and extremely significant
p ≤ 0.001 (∗∗∗ ). The error bars represent the SEM. The data are based on the results of three independent experiments. (C) Detection of ALV-J gp85 and fps
proteins in Fu-J (SDAU1005) viral stock infected CEF cells by western blot analysis. Line 1: control group; lines 2–4: cells treated with 1, 2, 4 μg/mL lamivudine.
TABLE 3 | Inhibitory effect of lamivudine on ALV reverse transcriptase activity.
Group Lamivudine added into
RT reaction (µg/mL)
CT value of real-time
PCR (mean ± SD)a
Copy number of RT
Products
Relative activity of reverse
transcriptaseb (%)
1 1 24.72 ± 0.23B 2.84 × 103 46
2 2 25.77 ± 0.18C 1.21 × 103 24
3 4 27.53 ± 0.19D 2.90 × 102 6
4 - 23.97 ± 0.23A 5.26 × 103 100
aCT values of real-time PCR followed by different superscript letter was significantly different (p < 0.05) based on Duncan’s multiple range test.
bThe relative activity of reverse transcriptase was calculated of copy numbers of RT products in each groups divided by copy number of RT products in group 4.
tumors grew slowly in chickens without lamivudine injection
at an early stage, although tumors grew more rapidly at a
later stage compared with those chickens without lamivudine
injection. Therefore, it would appear that lamivudine has an
inhibitory eﬀect on the early growth of subcutaneous tumors
but could not suppress virus replication or tumor growth
completely.
Lamivudine Can Reduce the Mortality of
Chickens Inoculated with Fu-J
(SDAU1005) Viral Stock Intraperitoneally
by Inhibiting Help Virus ALV-J Replication
Another animal model was established for rapid drug screening
using the Fu-J virus. Eighty 1-day-old chickens were divided
into four groups and inoculated with the same dose of Fu-
J virus intraperitoneally. Chickens in groups 5, 6, and 7 were
injected intramuscularly with 1, 2, and 4 mg lamivudine every
day for 7 days, while chickens in group 4 were injected with
the same dose of PBS to serve as a control group. Survival
rates were recorded, and viral loads in plasma were determined
by real-time PCR every week. The results showed that the
median survival for chickens in groups 5, 6, and 7 and the
control group was 21, 24, 26, and 19 days, respectively, while
the mortality rates were 100, 90, 70, and 100%, respectively
(Figure 2B). This indicated that lamivudine could prolong
the survival time and reduce the mortality rate in chickens
infected with Fu-J virus, although the use of drugs could not
prevent the growth of abdominal tumors. The real-time PCR
results illustrated a signiﬁcant reduction of SDAU1005 and
Fu-J plasma viral loads in chickens injected with lamivudine,
and this eﬀect was dose dependent, which could explain
the cause of mortality reduction in chickens (Figures 2C,D).
Furthermore, lamivudine had a more moderate inhibitory
eﬀect on Fu-J strain, which carry the v-fps oncogene than
SDAU1005. This might result from the diﬀerent inhibitory
mechanisms between SDAU1005 and Fu-J. Lamivudine could
inhibit replication of SDAU1005 by inhibiting its reverse
transcriptase activity, but the inhibition of Fu-J might have
resulted from the reduction of SDAU1005, which functions as
its helper virus and provides reverse transcriptase and other
proteins.
No Drug-resistant Mutants could be
Detected in Acute Subcutaneous
Sarcomas of Chickens
Chicken embryo ﬁbroblasts were infected with primary viral
stock and isolated viral stock, respectively, and maintained in
DMEM with 1 μg/ml lamivudine for 6 days. Helper virus
and replication-defective virus were quantiﬁed by real-time
PCR, and the inhibition ratio of lamivudine was calculated.
The ELISA results showed that lamivudine could inhibit the
replication of both primary virus and administered isolated virus.
However, no signiﬁcance was observed between primary virus
multiplication and administered isolated virus multiplication
during cell maintenance (Figure 3A). Moreover, the quantitative
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FIGURE 2 | Effect of lamivudine on Fu-J replication in chickens. (A) Growth of subcutaneous tumors induced by Fu-J virus in different groups. Administration
of lamivudine delayed the tumor occurrence time and slowed down the speed of tumor growth at the early stage. (B) Survival plots of chickens infected with Fu-J
virus intraperitoneally in different groups. Survival patterns of chickens in different groups showed a significant different from each other. (C) SDAU1005 plasma viral
loads post-inoculation determined by real-time PCR demonstrated that Lamivudine could inhibit SDAU1005 replication in chickens. (D) Fu-J plasma viral loads
post-inoculation determined by real-time PCR demonstrated that the replication of Fu-J virus was inhibited due to the reduction of SDAU1005. Differences in the
expression level were assessed by Student’s t-tests. Differences were considered highly significant when p ≤ 0.01 (∗∗ ) and extremely significant p ≤ 0.001 (∗∗∗). The
error bars represent the SEM. The data are representative of the results of three independent experiments.
data also revealed that there was no signiﬁcance observed
between the inhibition ratio of lamivudine on the replication
of both helper virus and replication-defective virus (Figure 3B).
In addition, the viral sequence coding for reverse transcriptase
in the ALV pol gene was ampliﬁed from primary virus and
isolated virus, and sequences were compared. However, no
regular mutations related to drug resistance were observed.
Above all, there was no detectable drug resistance mutations
that had occurred in the viral stock prepared from subcutaneous
tumors collected from chickens infected with primary viral
stocks.
DISCUSSION
Throughout history, ALV, especially ALV-J, has caused great
economic losses for the poultry husbandry in China (Gao
et al., 2010). Much research has been conducted to discover
or design agents for antiviral therapy (Qian et al., 2014;
Wei et al., 2015). However, no eﬀective vaccine or drug
agents are available at present due to the high mutation
rates of ALV-J. It appears that surveillance and elimination
of infected chickens are the most fundamental and eﬀective
way to control ALV-J since it is mainly transmitted vertically
from generation to generation (Weiss and Vogt, 2011).
Drug administration could also inhibit virus replication and
transmission to virus-free chickens, which could accelerate virus
control objectively.
Lamivudine is a typical antiviral agent, a pyrimidine
nucleoside, which can be phosphorylated in cells and inserted
into viral DNA in cyclic adenosine phosphate forms, leading to
the termination of DNA extension (Balzarini, 1994). In addition,
lamivudine has a strong inhibitory eﬀect on HIV by directly
inhibiting HIV reverse transcriptase activity (Tisdale et al., 1993;
Gray et al., 1995; Anderson, 2002). Currently, lamivudine has
been widely used for the treatment of hepatitis B and HIV with
a mature synthetic technique (Bernasconi and Battegay, 1998;
Anderson, 2002; Fung et al., 2011). Phylogenetic comparison of
HIV and ALV reverse transcriptases showed a 39.6% identify.
Given that reverse transcriptase played important roles in ALV
replication and infection, we considered lamivudine may also
have an inhibitory eﬀect on ALV; however, to the best of our
knowledge, no research had been conducted in this area till
date.
In this study, a series of experiments were conducted in
CEF cultures and 1-day-old chickens inoculated with an acute
transforming viral stock Fu-J (SDAU1005). In fact, this viral
stock consisted of two types of viruses: the replication-defective
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FIGURE 3 | Chicken embryo fibroblast (CEF) cells were infected with primary viral stock and administrated isolated viral stock respectively and
maintained in DMEM with or without 1 µg/mL lamivudine for 6 days, and ALV-p27 antigen was measured from cellular supernatant every day (A). Viral
RNA was extracted on the 7th day and both helper virus and replication-defective virus were quantitated by real-time PCR. Inhibition ratio of lamivudine was
calculated to estimate the inhibitory effect of lamivudine on primary viral stock and isolated viral stock (B). Differences in the expression level were assessed by
Student’s t-tests. The error bars represent the SEM. ns, no significant difference (p > 0.05).
virus Fu-J carrying the v-fps oncogene and its helper virus
ALV-J SDAU1005 (Chen et al., 2012; Wang et al., 2013b). Fu-J
(SDAU1005) viral stock was employed in this study because it
can rapidly induce ﬁbrosarcomas in chickens within 2 weeks.
In addition, there was a positive correlation between occurrence
time and growth speed of tumors and the viral infection dose.
This makes it more convenient for us to evaluate the inhibitory
eﬀect of lamivudine on ALV-J in chickens by recording and
analyzing several parameters within a relatively short period.
The results in cell cultures demonstrated that lamivudine could
inhibit the replication of both SDAU1005 and Fu-J viruses
and was dose dependent in the concentration range of 1–
4 μg/ml. Meanwhile, the animal experiment data showed that
lamivudine could slow down the growth and decrease the
sizes of the tumor, while prolonging the survival time and
delaying the mortality of infected chickens at an early stage by
decreasing the viral loads of both SDAU1005 and Fu-J virus
carrying the v-fps oncogene in chicken plasma. Furthermore,
the mechanism of the inhibitory eﬀect was elucidated. We
showed that lamivudine had an inhibitory eﬀect on ALV reverse
transcriptase reverse activity. Therefore, it seems that lamivudine
could inhibit ALV-J replication by competing with normal
nucleotides for reverse transcriptase binding and inhibited cDNA
transcription and extension, with a mechanism similar to that
of HIV inhibition. Given that the sequence of the pol gene,
which encoded reverse transcriptase, was conserved in diﬀerent
subgroups of ALV, we consider that lamivudine could inhibit
all subgroups of ALV strains other than ALV-J. Those results
suggested lamivudine might serve as a potential antisubgroup J
ALV therapy.
It is notable that the replication of helper virus ALV-J
SDAU1005 strain was blocked by lamivudine through inhibition
of the reverse transcriptase enzyme activity. However, the
replication-defective virus Fu-J could not encode reverse
transcriptase due to a deletion mutation of the pol gene with
the viral genome structure as follows: 5′ LTR-gag-fps-pol-
env-3′ LTR. Thus, it would be expected to rely entirely on the
helper virus for gag-, pol-, and env-encoded protein functions
to replicate and infect other host cells. We speculate that the
inhibitory capability of Fu-J virus in CEF cultured cells and
in chickens inoculated with Fu-J (SDAU1005) was due to the
inhibitory eﬀect of lamivudine on SDAU1005, which functions
as a helper virus of Fu-J. This study demonstrates that the
level of Fu-J virus replication correlated with that of SDAU1005,
which provided an insight into the relationships between the
replication-defective virus and its helper virus, as well as with
tumor processes.
Finally, it is important to highlight that lamivudine treatment
cannot kill the virus completely. In fact, when used alone for
HIV therapy, drug-resistant mutants can develop quickly due
to the high mutation rate of HIV during virus replication
(Boucher et al., 1993; Tisdale et al., 1993; Gu et al., 1994;
Smith et al., 1994). Therefore, highly active antiretroviral therapy
(HAART) using several combinations of drugs at the same
time is usually carried out for HIV treatment. In this study,
the growth rate of acute sarcoma was obviously increased at
the late stage, highlighting suspicion of whether the virus had
mutated to resist drug therapies. However, our experimental
data showed that even lamivudine at low concentration could
still inhibit the replication of the virus from administered
chickens, and the sequence of the pol gene coding for reverse
transcriptase did not illustrate any regular mutations, which
contributed to drug resistance. We conclude that no detectable
drug-resistant mutants developed in infected chickens treated
with lamivudine, during our study period. The increase in tumor
growth might result from unregulated tumor cell proliferation in
chickens. The same method was also performed to investigate
whether drug-resistant mutants had developed in the cell
supernatant of cultured CEFs maintained in DMEM with added
lamivudine. The results demonstrated that no drug-resistant
mutants were detected in cell supernatant. However, our latest
data showed that when the viral stock was passaged to the
38th generation in cultured CEFs maintained in DMEM with
lamivudine added, the replication of virus could not be inhibited
by lamivudine, which implied that drug-resistant mutants could
develop in vivo, and we intend to publish related data at a
later date. The possibility of drug-resistant mutants should be
considered during the treatment of ALV using lamivudine.
Therefore, it is necessary to use other drugs in a similar way
to that conducted in “HAART,” to avoid the risk of virus
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mutation and obtain a better therapeutic eﬀect. It is important
to emphasize that eradication of ALV in infected chickens is
one of the most fundamental measures for ALV prevention and
control. Drug administration is just a supplementary means of
controlling virus transmission and accelerates the puriﬁcation
process.
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